Upload
others
View
4
Download
0
Embed Size (px)
Citation preview
Patency rates and clinical results of a dedicated closed-cell design stent for thetreatment of iliac vein lesion
Michael K. W. Lichtenberg MD, FESCVascular Centre Arnsberg / German Venous Centre Arnsberg
Conflict of Interest - Disclosure
Within the past 12 months, I or my spouse/partner have had a financial
interest/arrangement or affiliation with the organization(s) listed below.
Affiliation/Financial Relationship Company
1. Honoraria for lectures: CR Bard, Veniti, AB Medica, Volcano, Optimed
GmbH, Straub Medical, Terumo, Biotronik, Veryan
2. Honoraria for advisory board activities: Veniti, Optimed GmbH, Straub
Medical, Biotronik, Veryan, Boston Scientific
3. Participation in clinical trials: Biotronik, CR Bard, Veryan, Straub Medical,
Veniti, TVA Medical, Boston Scientific, LimFlow
4. Research funding: Biotronik, Boston Scientific, Veryan, Veniti, AB Medica
• Self-expandable
• Crush resistant across length of stent
• Sufficient chronic outward force
• Sufficient wall coverage
• Flexibility sufficient to resist kink at physiological angles
• Durability allowing repeated shortening, twisting, and bending at the groin
• Minimal foreshortening on deployment and balloon dilation
• Predictable, consistent deployment
Desired Venous Stent Attributes
Goal… Ideal BALANCE strength, flexibility, and lumen quality.
C6, 58 year female with chronic outflow obstruction
2 Sinus XL Stent (22 x 80 mm)4 x Veniti Vici Stent (16 x 120 mm + 14 x 60 mm)
Cell Architecture
• All Internal inflection points are connected by bridging elements.
• Regular peak-to-peak connections.
• Uniform surface, regardless of the degree of bending.
• Generally less flexible than a open-cell design.
Closed-cell stents have an intrinsically greater potential to scaffold
and support thrombogenic material away from the blood flow.
Open-cellClosed-cellBasic design concept.
Cell shape and
bridging element
designs varies among
stent manufacturers.
VICI VENOUS STENT® DESIGN
Self-expanding nitinol- 12, 14, and 16mm diameter
- 60, 90, and 120mm length.
Closed-cell Geometry
Designed for
Strength High crush resistance
Flexibility Multi-directional
Uniform shape (end-to-end)
Lumen quality
Coverage No gaps, closed-cell
Deployment Predictable placement Closed-Cell
Alternating Curved Bridges
Flexibility
Sinusoidal rings
24 Struts per ring
Strength
Closed Cell Open Cell
Design Attributes • All struts interconnected • Not all struts interconnected
Performance
Crush Resistance ++ +Flexibility + ++Coverage ++ +
Performance Characteristics
VICI Lumen QualityUniform Strength and Coverage
Gap
Gap No Gap
24 Struts12 Struts8 Struts4 Struts
Closed-cellOpen-cellOpen-cell
Str
en
gth
Co
ve
rag
e
VICI STENT
VIRTUS Feasibility Trial Design
ObjectiveAssess safety & effectiveness in achieving patency of target venous lesion through 12-M post stent placement
Safety MAEs @ 30 days
Effectiveness Primary Patency @ 12-M
PrincipalInvestigators
Dr. William Marston Dr. Mahmood Razavi
Study DesignProspective, multicenter, single arm non-randomized, up to 45 sites worldwide
PatientPopulation
200 subjects with clinically significant chronic non-malignant obstruction of the iliofemoral venous segment – first 30 were feasibility.
Etiologies: Post Thrombotic (75%); Non Thrombotic (25%)
Core Labs
Venography: SyntactxIVUS: St. LukesDUS: VasCore/MGHX-Ray: Syntactx
Non-thrombotic
Post-thrombotic
Image Courtesy of Mr. Stephen Black
Image Courtesy of Mr. Mahmood Razavi
Demographics & Medical HistoryFemale 24 (80%) Male 6 (20%)
Age 44.4 ±14.1 years
CEAP* Baseline
0 3% (pain by VCSS Score of ≥2)
1 0%
2 0%
3 47%
4 40%
5 7%
6 3%
Etiology
PTS 63%
NIVL 37%
Target Lesion Location
Lesion1 Location
Patients N = 30
Left N = 25 (83%)
Right N = 5(17%)
CIV lesions 26/30 (87%)
EIV lesions 18/30 (60%)
CIV & EIV lesions 15/30 (50%)
Lesions that extended into CFV2 9/30 (30%)
Average Target Lesion Length
11.9 ±6.7 cm
1. Some patients have more than 1 lesion or lesion extends in multiple vein segments2. No lesions were isolated to the CFV alone
Improvement in % Lesion Stenosis
% Lesion StenosisPre Procedure by Venogram (Site
Reported)
% Lesion StenosisPost Procedure by
Venogram (Site Reported)
Full Cohort N=30 85.2±17.2 1.8±3.8
Gender
Female 80% 88.4±15 1.5±3.6
Male 20% 73.2±19.4 2.8±4.5
Etiology
PTS 63% 89.3±16.3 2.1±4.2
NIVL 37% 77.5±16.1 1.4±3.1
Patency by Duplex Ultrasound(Corelab Analysis)
Courtesy of Dr. Ediberto Soto-Cora
Patency Results of Feasibility Cohort (N=30)
Primary Patency1 Secondary Patency
1- M 93% 100%
6 – M 90% 100%
12 – M 93% 97%
Safety Endpoint Results
Primary Safety Endpoint through 30 Days (n=30)
n %
Composite Major Adverse Events (MAE) 0 0
Device or procedure-related death 0 0
Device or procedure-related bleeding 0 0
Device or procedure-related vessel injury 0 0
Device or procedure-related DVT (non-target vessel segment)*
0 0
Clinically significant PE 0 0
Embolization of stent 0 0
No MAEs @ 30 days
Patient Outcomes in the VIRTUS Trial
Using QOL and Patient Outcome Data to Evaluate How Patients Feel
Three different scales were used in VIRTUS to evaluate QOL VCSS
VAS
CIVIQ-20
VCSS Pain Scale
45% had “substantial symptomatic improvement” (VCSS ≥2 ) @12-M
VAS Scale
CIVIQ-20
Arnsberg Venous RegistryVENITI VICI VENOUS STENT® System
ObjectiveAssess safety & effectiveness in achieving patency of target venous lesion through 36 months post stent placement (VENITI VICI Stent)
Effectiveness Primary Patency @ 12-M
Principle Investigators Dr. Michael Lichtenberg Dr. Rick de Graaf
Study DesignOngoing prospective, single arm, single center non-randomized registry FU 1 (4 weeks), FU 2 (6 months), FU 3 (12 months), FU 4 (24 months), FU 5 (36 months)
Patient PopulationSubjects with clinically significant chronic non-malignant obstruction of the iliofemoralvenous segment
Demographics N=90
Age in years(mean ± SD [range]) 57.4 ± 16.4 [19-84]
GenderMaleFemale
47.8% (N=43)52.2% (N=47)
EthnicityCaucasian 100% (N=90)
Medical history N=90
Coagulation disorder 4.4% (N=4)
Pulmonary embolism 24.4% (N=22)
Deep vein thrombosis 47.8% (N=43)
History of cancer 14.4% (N=13)
Lesion analysis N=90
Sides treatedBothLeftRight
7.8% (N=7)74.4% (N=67)17.8% (N=16)
Lesion location(s)
Left:Common iliac veinExternal iliac veinCommon femoral veinCommon iliac vein, external iliac veinCommon iliac vein, external iliac vein, common femoral veinExternal iliac vein, common femoral vein
Right:Common femoral veinCommon iliac veinExternal iliac veinCommon iliac vein, external iliac veinCommon iliac vein, external iliac vein, common femoral veinExternal iliac vein, common femoral vein
Both:External iliac (R), common iliac (L) veinExternal iliac (R), common iliac (L), external iliac (L) veinCommon iliac (R+L), external iliac (L) veinCommon iliac (R+L), external iliac (R+L), common femoral (L) veinCommon iliac (R+L), external iliac (R+L), common femoral (R+L) vein
37.8% (N=34)4.4% (N=4)2.2% (N=2)17.8% (N=16)8.9% (N=8)3.3% (N=3)
2.2% (N=2)3.3% (N=3)6.7% (N=6)1.1% (N=1)1.1% (N=1)3.3% (N=3)
1.1% (N=1)2.2% (N=2)2.2% (N=2)1.1% (N=1)1.1% (N=1)
64 / 90 (71%) patients: Postthrombotic
26 / 90 (29%) patients: NIVL
Effectiveness analysis
0
10
20
30
40
50
60
70
80
90
100
FU 4 w FU 6 mo FU 12 mo
% Patentcy analysis
NIVL PTS
N=50N=82 N=21
100 % 100 % 100 %
97% 90 %87 %
0
2
4
6
8
10
12
14
Baseline FU1 FU2 FU3
Mean VCSS score (±SD)
N=90 N=82 N=50 N=21
9.2
5.34.9
4.3
Claudication, Pain, Swelling,
Ulceration improvement
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Baseline FU1 FU2 FU3
Mean CEAP score (±SD)
N=90 N=82 N=50 N=21
3.6
2.6 2.7
2.4
Conclusions
• Initial 6 and 12-Month efficacy data in the VIRTUS Trial and
Arnsberg Registry are better than reported data:NIVL PTS
Primary patency: 100% 87%Secondary Patency: 100% 97%
• Safety data is positive
• Patients feel substantially better
85% of population showed symptomatic improvement after venous stenting (VCSS ≥2) at 12-Months
45% had “substantial symptomatic improvement” (VCSS ≥2 ) at 12-M
• Venous anatomy and disease require dedicated venous stents
27
Patency rates and clinical results of a dedicated closed-cell design stent for thetreatment of iliac vein lesion
Michael K. W. Lichtenberg MD, FESCVascular Centre Arnsberg / German Venous Centre Arnsberg